A Comparative Study of Isradipine and Nifedipine in the Monotherapy of Mild to Moderate Hypertension in the Ghanaian.
No Thumbnail Available
Date
1994
Journal Title
Journal ISSN
Volume Title
Publisher
Ghana Medical Journal
Abstract
Clinical experience with the new dihydropyridine
calcium antagonist. isradipine. is reported. Isradipine
was compared with nifedipine in a multicentre
open. parallel group. clinical therapeutic trial involving
70 patients with mild to moderate hypertension. A four week placebo washout period was followed
by a 12 week active treatment period during
which patients were randomized to receive cither 2.5
mg isradipine twice daily (n = 40) or 10 mg nifedipine
three times daily ( n=30). Isradipine significantly
reduced sitting systolic /diastolic blood pressures
from 176.7 ± 21.0/l06.7±7.0mmHg to
l42.9± 15/93.1±7.7mmHg (p< 0.001) at the end of
12 weeks. Similarly. nifedipine reduced sitting systolic/diastolic blood pressures from
170.2±1 9.5/1 06.2±7.4mmHg to 139. 1±9.7/92. 1±7.8
mmHg (p< 0.001). Normalisation (diastolic<90
mmHg) rates were 67% and 60% for isradipine and
nifedipine respectively while good response (diastolic fall > 10mmHg) rate was over 85% on cither
drug. Heart rate did not significantly change
with either treatment. Three (3) patients taking isradipine
experienced headache and 7 patients taking
nifedipine had drug related adverse effects (5 had
headache. I insomnia and I first dose hypotension).
Therapy was Withdrawn in 4 patients taking nifedipine
and 1 taking isradipine. It is concluded that isradipine
is comparable to nifedipine and is an effective and well-tolerated antihypertensive agent In the
Ghanaian.
Description
Journal Article
Keywords
isradipine, nifedipine, Hypertension, Efficacy, tolerability